PDA Announces Nearly 100 Exhibitors at the 19th Universe of Pre-Filled Syringes and Injection Devices Conference

The largest conference/exhibition dedicated to this critical technology for the delivery of biological and traditional medicines returns to in-person meeting in 2022

BETHESDA, Md., Sept. 29, 2022 /PRNewswire-PRWeb/ -- The Parenteral Drug Association, Inc. (PDA), today announced that 96 exhibitors will present their technologies at the first in-person Universe of Pre-Filled Syringes and Injection Devices (UPS) Conference since 2019. It will be held in Palm Springs, Ca., 18-19 Oct. The 2020 and 2021 conferences were held as virtual events.

PDA's UPS Conference and Exhibition is the largest in the world of its kind dedicated to this critical technology for the delivery of biological and traditional sterile medicines to patients.

"The organizing committee is delighted to welcome delegates back to the PDA Universe of Pre-Filled Syringes and Injection Devices Conference," said Mathias Romacker, committee co-chair and executive advisor, Kymanox. "This year we are finally back to meet in person and so many new topics are there to be discussed. Please join us for the 'New Normal in injectable Drug Delivery.'"

The UPS conference will explore the future of pharmaceutical devices, such as rapid technological advances, that will push the industry ahead while bringing together industry experts to share their experiences, new developments, regulatory considerations, challenges, and industry trends in this exciting area.

Continued advances in materials of construction, manufacturing processes, injection processes and safety devices, and other technology improvements create a dynamic environment in the drug delivery device arena. Regulatory requirements, industry experience, and evolving market trends are critical considerations to ensure a complete understanding of the application of pre-filled syringes or other pre-filled containers and injection devices to drug delivery. The challenges of new product introduction and support of existing products require that companies be aware of new developments.

"Coming on the heels of our very successful PDA/FDA Joint Regulatory Conference in September, which also returned to in-person format for the first time since 2019, PDA is looking forward to a large gathering of the technical experts in this field," said Richard Johnson, CEO/president of PDA. "Afterward, we are sponsoring our fourth 2022 workshop on the EMA's Annex 1, which was finalized by the EU in August."

The 2022 PDA Annex 1 Workshops highlight critical changes in the new regulation and include interactive sessions to provide attendees with a clear understanding of and means to implement all the requirements of the rule. The Palm Springs workshop, 20-21 Oct., is the fourth sponsored by PDA in 2022. Additional workshops are anticipated for 2023.

Members of the press can request press passes to these events here: https://www.pda.org/about-pda/press-pass-request-form.

About PDA – Connecting People, Science and Regulation®
The Parenteral Drug Association (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of over 10,500 members worldwide. PDA is an ANSI accredited Standards Developing Organization. Go to http://www.pda.org/footer/about-pda to learn more.

Media Contact

Walter Morris, www.pda.org, 1 301-656-5900, [email protected]

SOURCE www.pda.org